DalsnaFinance

Royalty Pharma $RPRX

Health Care

Russell 1000 New York
Create a scorecard
$63.75
+1.60 (+2.57%)
As of Oct 22, 2026, 9:33 PM EDT
Price history
Loading chart…

Royalty Pharma (RPRX) is trading up at $63.75 (+2.57%), as of the latest quote. It is a Russell 1000 constituent in the Health Care sector.

IPO: June 16, 2020 · $28.00 offering · NASDAQ · View IPO details →

Royalty Pharma revenue & net income history (FY2018–FY2025)

RevenueNet incomeNet margin (right axis, %)
$2.38B$1.19B$0FY2018 revenue: $1.79BFY2018 net income: $1.38B · Net margin 76.8%'18FY2019 revenue: $1.81BFY2019 net income: $2.35B · Net margin 129.4%'19FY2020 revenue: $2.12BFY2020 net income: $975.0M · Net margin 45.9%'20FY2021 revenue: $2.29BFY2021 net income: $619.7M · Net margin 27.1%'21FY2022 revenue: $2.24BFY2022 net income: $42.8M · Net margin 1.9%'22FY2023 revenue: $2.35BFY2023 net income: $1.13B · Net margin 48.2%'23FY2024 revenue: $2.26BFY2024 net income: $859.0M · Net margin 37.9%'24FY2025 revenue: $2.38BFY2025 net income: $770.9M · Net margin 32.4%'250%50%100%150%FY2018 net margin: 76.8%FY2019 net margin: 129.4%FY2020 net margin: 45.9%FY2021 net margin: 27.1%FY2022 net margin: 1.9%FY2023 net margin: 48.2%FY2024 net margin: 37.9%FY2025 net margin: 32.4%
Royalty Pharma annual financial statements
FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue$1.79B$1.81B$2.12B$2.29B$2.24B$2.35B$2.26B$2.38B
Growth (year over year)—+1.1%+17.0%+7.9%−2.3%+5.2%−3.9%+5.1%
Operating income$1.36B$2.62B$1.60B$1.43B$307.1M$1.49B$1.29B$1.56B
Operating margin76.0%144.6%75.2%62.5%13.7%63.4%57.1%65.6%
Net income$1.38B$2.35B$975.0M$619.7M$42.8M$1.13B$859.0M$770.9M
Net margin76.8%129.4%45.9%27.1%1.9%48.2%37.9%32.4%
EPS (diluted)——$1.32$1.49$0.10$2.53$1.91$1.78
Balance sheet
Cash and equivalents$1.92B$246.2M$1.01B$1.54B$1.71B$477.0M$929.0M$618.7M
Total assets—$12.4B$16.0B$17.5B$16.8B$16.4B$18.2B$19.6B
Total liabilities—$6.31B$6.12B$7.27B$7.29B$6.30B$7.88B$9.91B
Long-term debt—$5.96B$5.82B$7.10B$6.12B$6.14B$6.61B$8.57B
Shareholders' equity$4.55B$6.14B$9.90B$10.2B$9.53B$10.1B$10.3B$9.71B
Cash flow
Operating cash flow$1.62B$1.67B$2.03B$2.02B$2.14B$2.99B$2.77B$2.49B
Share buybacks$0$4.27M$0$0$0$304.8M$229.7M$1.23B

From Royalty Pharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

About Royalty Pharma

Headquarters
New York, New York From SEC filings, Oct 2026

Recent News (6)

More Health Care stocks

Browse all companies →